ONVO - Organovo Holdings, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
1.7400
+0.0100 (+0.58%)
At close: 04:00PM EDT
1.7200 -0.02 (-1.15%)
After hours: 04:07PM EDT
Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Short-term KST

Short-term KST

Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
    9M+
Previous Close1.7300
Open1.6900
Bid1.7400 x 2900
Ask1.8100 x 3200
Day's Range1.6900 - 1.8206
52 Week Range1.3700 - 3.7200
Volume28,520
Avg. Volume26,922
Market Cap15.163M
Beta (5Y Monthly)0.89
PE Ratio (TTM)N/A
EPS (TTM)-1.4000
Earnings DateFeb 08, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for ONVO

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Insider Monkey

    Cathie Wood is Selling These 12 Stocks in 2023

    In this article, we will take a look at Cathie Wood selling these 12 stocks in 2023. To see more such companies, go directly to Cathie Wood is Selling These 5 Stocks in 2023. After a bruising 2022, Cathie Wood’s funds slowly started to recover this year, thanks to the broader rally in the stock […]

  • GlobeNewswire

    Organovo Announces FXR Program

    Lead Molecule Poised for Phase 2 in IBDSAN DIEGO, March 21, 2023 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (NASDAQ: ONVO), a clinical stage biotechnology company that is focused on developing novel human therapies with demonstrated function in high fidelity three-dimensional (3D) tissues that recapitulate key aspects of human disease, today announced a clinical program for FXR 314, an FXR agonist that has completed initial clinical trials. FXR314 is a drug with safety and tolerability after da

  • Simply Wall St.

    Will Organovo Holdings (NASDAQ:ONVO) Spend Its Cash Wisely?

    We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...

  • GlobeNewswire

    Organovo Announces Target Validation Ahead of Schedule, Accelerating Timeline for First Crohn’s Disease Drug Candidates

    SAN DIEGO, Nov. 15, 2022 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq: ONVO), a three-dimensional biology (3D biology) company focused on delivering scientific and medical breakthroughs using novel technologies including 3D bioprinting, today announced that it has successfully advanced the use of its first inflammatory bowel disease (IBD) model and has achieved the next milestone, target validation. The company announced in May 2022 that it had achieved a successful Crohn’s disease model

  • GlobeNewswire

    Organovo to Participate in the H.C. Wainwright 24th Annual Global Investment Conference

    SAN DIEGO, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (NASDAQ: ONVO), an early-stage biotechnology company that is focusing on building high fidelity, 3D tissues that recapitulate key aspects of human disease, today announced that Keith Murphy, Executive Chairman, will participate in the H.C. Wainwright 24th Annual Global Investment Conference, September 12 - 14, 2022. Organovo plans to advance drugs discovered in its cutting-edge human 3D disease models in inflammatory bowel dis

  • GlobeNewswire

    Organovo Announces Postponement of Annual Meeting of Stockholders

    SAN DIEGO, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq: ONVO), an early-stage biotechnology company that is focusing on building high fidelity, 3D tissues that recapitulate key aspects of human disease (the “Company”), today announced that its 2022 Annual Meeting of Stockholders (the “2022 Annual Meeting”) that was scheduled to be held at 9:00AM (Pacific Time) on Wednesday, September 7, 2022 has been postponed to October 12, 2022 at 9:00AM (Pacific Time), a date determined

  • Simply Wall St.

    We're Not Very Worried About Organovo Holdings' (NASDAQ:ONVO) Cash Burn Rate

    There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...